Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Current Assets (2018 - 2025)

Historic Current Assets for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $165.0 million.

  • Whitehawk Therapeutics' Current Assets rose 11345.92% to $165.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165.0 million, marking a year-over-year increase of 11345.92%. This contributed to the annual value of $61.3 million for FY2024, which is 5080.75% down from last year.
  • Per Whitehawk Therapeutics' latest filing, its Current Assets stood at $165.0 million for Q3 2025, which was up 11345.92% from $178.7 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Current Assets peaked at $232.6 million during Q1 2025, and registered a low of $37.4 million during Q2 2021.
  • Its 5-year average for Current Assets is $131.5 million, with a median of $135.6 million in 2022.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Current Assets surged by 23249.46% in 2022, and later crashed by 5080.75% in 2024.
  • Quarter analysis of 5 years shows Whitehawk Therapeutics' Current Assets stood at $151.3 million in 2021, then rose by 19.01% to $180.0 million in 2022, then plummeted by 30.8% to $124.6 million in 2023, then tumbled by 50.81% to $61.3 million in 2024, then skyrocketed by 169.28% to $165.0 million in 2025.
  • Its Current Assets stands at $165.0 million for Q3 2025, versus $178.7 million for Q2 2025 and $232.6 million for Q1 2025.